ELISA/assay

Human alpha Synuclein Oligomer ELISA Kit

MBS043824

48-Strip-Wells

435 USD

ELISA Kit

Human alpha Synuclein Oligomer ELISA Kit

alpha Synuclein Oligomer

Alpha-synuclein; Alpha-synuclein; alpha-synuclein; synuclein alpha-140; non A-beta component of AD amyloid; synuclein, alpha (non A4 component of amyloid precursor); Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP

alpha-SNCO

SNCA; SNCA; PD1; NACP; PARK1; PARK4; NACP; PARK1; NACP

SYUA_HUMAN

Human

2425

No significant cross-reactivity or interference between this analyte and analogues is observed.

Store all reagents at 2-8 degree C

Samples: Undiluted original Human body fluids, tissue homogenates, secretions or feces samples. Assay Type: Sandwich. Detection Range: 0.625 ng/ml - 20 ng/ml. Sensitivity: 0.1 ng/ml.

Intra-assay Precision: Intra-assay CV (%) is less than 15%. Inter-assay Precision: Inter-assay CV (%) is less than 15%. [CV(%) = SD/mean ×100].

Neurobiology

Background/Introduction: This Quantitative Sandwich ELISA kit is only for in vitro research use only, NOT for drug, household, therapeutic or diagnostic applications! This kit is intended to be used for determination the level of A-SNCO (hereafter termed "analyte") in undiluted original Human body fluids, tissue homogenates, secretions or feces samples. This kit is NOT suitable for assaying non-biological sources of substances.

586067

P37840.1

13,109 Da

Alpha-synuclein Signaling Pathway (137913); Alzheimer's Disease Pathway (83097); Alzheimer's Disease Pathway (509); Alzheimers Disease Pathway (672448); Amyloids Pathway (366238); Disease Pathway (530764); EGFR1 Signaling Pathway (198782); Parkin-Ubiquitin Proteasomal System Pathway (700638); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377)

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]

SNCA: a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson s disease. A major component of amyloid plaques in the brains of patients with Alzheimer s disease. Two alternatively spliced isoforms transcripts have been identified. Protein type: Adaptor/scaffold. Chromosomal Location of Human Ortholog: 4q21. Cellular Component: Golgi apparatus; nuclear outer membrane; mitochondrion; rough endoplasmic reticulum; lysosome; fibril; extracellular region; terminal button; inclusion body; cell cortex; cytosol; mitochondrial respiratory chain complex I; actin cytoskeleton; platelet alpha granule membrane; synaptic vesicle; growth cone; perinuclear region of cytoplasm; axon; cytoplasm; plasma membrane; ribosome; cell junction; nucleus. Molecular Function: identical protein binding; protein domain specific binding; histone binding; zinc ion binding; kinesin binding; ferrous iron binding; microtubule binding; caspase inhibitor activity; beta-tubulin binding; magnesium ion binding; phosphoprotein binding; protein N-terminus binding; Hsp70 protein binding; calcium ion binding; oxidoreductase activity; dynein binding; protein binding; copper ion binding; phospholipase binding; phospholipid binding; fatty acid binding; tau protein binding; alpha-tubulin binding. Biological Process: regulation of long-term neuronal synaptic plasticity; negative regulation of serotonin uptake; regulation of acyl-CoA biosynthetic process; adult locomotory behavior; positive regulation of apoptosis; mitochondrial membrane organization and biogenesis; negative regulation of norepinephrine uptake; microglial cell activation; positive regulation of endocytosis; response to lipopolysaccharide; negative regulation of caspase activity; dopamine biosynthetic process; negative regulation of monooxygenase activity; negative regulation of transcription from RNA polymerase II promoter; fatty acid metabolic process; positive regulation of neurotransmitter secretion; regulation of dopamine secretion; negative regulation of dopamine uptake; negative regulation of histone acetylation; calcium ion homeostasis; negative regulation of exocytosis; response to magnesium ion; negative regulation of protein amino acid phosphorylation; behavioral response to cocaine; receptor internalization; phospholipid metabolic process; synapse organization and biogenesis; fibril organization and biogenesis; dopamine uptake; response to iron(II) ion; negative regulation of neuron apoptosis; positive regulation of receptor recycling; aging; response to drug; caspase activation; neutral lipid metabolic process; protein destabilization; regulation of glutamate secretion; negative regulation of microtubule polymerization; regulation of macrophage activation; positive regulation of peptidyl-serine phosphorylation; negative regulation of dopamine metabolic process; organelle ATP synthesis coupled electron transport; regulation of locomotion; synaptic vesicle endocytosis; positive regulation of release of sequestered calcium ion into cytosol; regulation of excitatory postsynaptic membrane potential; negative regulation of transporter activity; negative regulation of apoptosis. Disease: Parkinson Disease 4, Autosomal Dominant; Parkinson Disease 1, Autosomal Dominant; Dementia, Lewy Body

48-Strip-Wells

435 USD

96-Strip-Wells

600